Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline

• Dogwood highlighted Halneuron injection, a tetrodotoxin-based Nav1.7 blocker, as its lead non-opioid program for chemotherapy-induced neuropathic pain.
• Phase 2b HALT-CINP-203 final data remain projected for fall 2026; interim analysis set sample size at 210-240 patients for 80%-85% power.
• Interim results in 97 patients showed a treatment effect versus placebo, including a durable response pattern in refractory patients; dropouts about 4.4%.
• Pro forma cash was USD 13.2 million as of March 31, 2026; shares outstanding were 33,553.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.